Literature DB >> 9767541

Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats.

J Chao1, J J Zhang, K F Lin, L Chao.   

Abstract

BACKGROUND: The tissue kallikrein-kinin system has been shown to play a role in cardiac and renal functions. In this study, we investigated the ability of kallikrein gene delivery to reverse salt-induced cardiac hypertrophy and renal injury in Dahl salt-sensitive rats.
METHODS: Adenovirus harboring the human tissue kallikrein gene, Ad.CMV-cHK, was delivered intravenously into Dahl salt-sensitive rats suffering from hypertension, cardiac hypertrophy and renal damage induced by a high salt diet (4% NaCl) for four weeks.
RESULTS: Expression of human kallikrein mRNA was detected in rat kidney, heart, aorta and liver, and immunoreactive human kallikrein levels were measured in the serum and urine of rats receiving gene delivery. A single injection of Ad.CMV-cHK caused a significant reduction of blood pressure for more than two weeks. Kallikrein gene transfer caused left ventricular mass reduction and elevated glomerular filtration rate, renal blood flow, urinary excretion, urinary kinin, nitrite/nitrate content, cGMP and cAMP levels. Morphological investigations showed that kallikrein gene transfer caused a significant reversal in salt-induced tissue and organ damage. In the heart, cardiac hypertrophy and fibrosis were reduced, and in the kidney, both glomerular sclerotic lesions and tubular damage were reversed.
CONCLUSIONS: Adenovirus-mediated kallikrein gene delivery is effective in reversing salt-induced cardiac hypertrophy and renal injury in Dahl-salt sensitive rats.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9767541     DOI: 10.1046/j.1523-1755.1998.00104.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  10 in total

1.  Sodium bicarbonate loading limits tubular cast formation independent of glomerular injury and proteinuria in Dahl salt-sensitive rats.

Authors:  Sarah C Ray; Bansari Patel; Debra L Irsik; Jingping Sun; Hiram Ocasio; Gene R Crislip; Chunhua H Jin; JianKang Chen; Babak Baban; Aaron J Polichnowski; Paul M O'Connor
Journal:  Clin Sci (Lond)       Date:  2018-06-20       Impact factor: 6.124

Review 2.  Kallikrein-kinin in stem cell therapy.

Authors:  Julie Chao; Grant Bledsoe; Lee Chao
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

Review 3.  Gene therapy of hypertensive vascular injury.

Authors:  Y Chu; F M Faraci; D D Heistad
Journal:  Curr Hypertens Rep       Date:  2000-02       Impact factor: 5.369

4.  Association of functional kallikrein-1 promoter polymorphisms and acute kidney injury: a case-control and longitudinal cohort study.

Authors:  Paweena Susantitaphong; Mary C Perianayagam; Sun Woo Kang; Wenyi Zhang; Fangwen Rao; Daniel T O'Connor; Bertrand L Jaber
Journal:  Nephron Clin Pract       Date:  2013-04-25

Review 5.  The kallikrein-kinin system in health and in diseases of the kidney.

Authors:  Masao Kakoki; Oliver Smithies
Journal:  Kidney Int       Date:  2009-02-04       Impact factor: 10.612

6.  Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans.

Authors:  Kui Liu; Quan-Zhen Li; Angelica M Delgado-Vega; Anna-Karin Abelson; Elena Sánchez; Jennifer A Kelly; Li Li; Yang Liu; Jinchun Zhou; Mei Yan; Qiu Ye; Shenxi Liu; Chun Xie; Xin J Zhou; Sharon A Chung; Bernardo Pons-Estel; Torsten Witte; Enrique de Ramón; Sang-Cheol Bae; Nadia Barizzone; Gian Domenico Sebastiani; Joan T Merrill; Peter K Gregersen; Gary G Gilkeson; Robert P Kimberly; Timothy J Vyse; Il Kim; Sandra D'Alfonso; Javier Martin; John B Harley; Lindsey A Criswell; Edward K Wakeland; Marta E Alarcón-Riquelme; Chandra Mohan
Journal:  J Clin Invest       Date:  2009-04       Impact factor: 14.808

Review 7.  A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development Concept.

Authors:  Makoto Katori; Masataka Majima
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-07

Review 8.  Genetically‑modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)‑based targeted therapy (Review).

Authors:  Marina Devetzi; Maria Goulielmaki; Nicolas Khoury; Demetrios A Spandidos; Georgia Sotiropoulou; Ioannis Christodoulou; Vassilis Zoumpourlis
Journal:  Int J Mol Med       Date:  2018-01-03       Impact factor: 4.101

9.  A renal-cerebral-peripheral sympathetic reflex mediates insulin resistance in chronic kidney disease.

Authors:  Wei Cao; Meng Shi; Liling Wu; Zhichen Yang; Xiaobing Yang; Hongfa Liu; Xin Xu; Youhua Liu; Christopher S Wilcox; Fan Fan Hou
Journal:  EBioMedicine       Date:  2018-11-11       Impact factor: 8.143

10.  The lupus-susceptibility gene kallikrein downmodulates antibody-mediated glomerulonephritis.

Authors:  Q-Z Li; J Zhou; R Yang; M Yan; Q Ye; K Liu; S Liu; X Shao; L Li; X-J Zhou; E K Wakeland; C Mohan
Journal:  Genes Immun       Date:  2009-03-05       Impact factor: 2.676

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.